Disease index

benign prostatic hyperplasia

Urology · 2008–2010

6decisions
3medicines
0carried consumer input
0individual submissions

Every decision here pre-dates the consumer comments facility, so no input would be recorded either way.

Every decision

MedicineMeetingOutcomeConsumer input
dutasteride with tamsulosin hydrochloride Treatment of moderate to severe lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) where treatment has been initiated by a urologist. Nov 2010 Recommended with restriction no section in document
tamsulosin hydrochloride Lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) Nov 2010 Recommended with restriction unclear
dutasteride treatment of benign prostatic hyperplasia (BPH) in men over 50 years who meet certain criteria Jul 2009 Not recommended no section in document
dutasteride Treatment, in combination with an alpha-antagonist, of lower urinary tract symptoms due to benign prostatic hyperplasia (BPH) where treatment is initiated by a… Nov 2009 Recommended with restriction no section in document
tamsulosin hydrochloride Relief of lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Mar 2008 Not recommended no section in document
tamsulosin hydrochloride Treatment of lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Nov 2008 Recommended no section in document

Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 0 of 0 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.